AAN

EpiFinder, a mobile health application, predicted either an epilepsy syndrome or alternative diagnosis with 86.8% accuracy.

Genentech's global head of Neuroscience clinical development detailed the company's commitment to treating the progressive form of multiple sclerosis.

Montes' team found benefits in motor function, walking ability, and fatigue in patients to undergo nusinersen (Spinraza) for spinal muscular atrophy.

The Global Head of Neurodegeneration for Genentech talks about the progress of 2 promising monoclonal antibodies.

The vice president of Development Sciences for Biogen shared developments to come of the international MS PATHS collaboration.

Children receiving AVXS-101 have shown such improvement that researchers are calling for an update to the CHOP-INTEND scale used to track their progress.

Patients from 2 demographically-different studies switching from interferon therapy to Aubagio reported similar improvements.

The executive vice president and chief medical officer of Biogen explained how crucial it is for potential DMTs to attacki the alpha-synuclein protein.

The director of the Sports Neurology Program at Norton Healthcare and head of the NCAA Headache Task Force discussed trends in his popularizing field.

Patients who had previously failed ≥2 preventative migraine treatments were effectively treated with galcanezumab, especially when compared to placebo.

Results from Alder Biopharmaceutical’s phase 3 study demonstrated reductions in migraine following quarterly infusions of both 100 mg and 300 mg eptinezumab versus placebo in patients with episodic migraines.

Lead author Alexander D. Rae-Grant, MD, explains the measures taken to ensure the panel got their 16-year multiple sclerosis recommendations update right.

Researchers found that 100U of incobotulinumtoxinA significantly reduced unstimulated salivary flow rate during the 16-week trial and through the 48-week extension.

Already tasked with a burdensome regimen of therapy for nerve damage, some patients may just be looking for simpler relief.

The American Academy of Neurology has issued 30 recommendations for clinicians regarding disease-modifying therapies for multiple sclerosis.

The investigative therapy for SMA reported various efficacy results in a phase 3 extension trial.

Among patients with MS who began ocrelizumab treatment in the open-label extension, MRI lesion activity was almost completely suppressed.

A new study finding that 50% of low income Latino patients with MS suffer from depression is coupled with recent reports on their exclusion from clinical research.

How a litany of treatment options could be just a single breakthrough drug away.

How the brain processes thought and action can be heavily influenced by the size of the network it's exposed to.

Trial results on the recently FDA-approved gammaCore device will be presented at the American Academy of Neurology (AAN) annual meeting.

The investigatory therapy for secondary progressive MS returned even more promising post hoc analysis prior to its FDA consideration.

A wrist-worn neuromodulation device delivers a nerve stimulation pattern tailored to the patient’s tremor.

The investigational therapy is first being researched for safety and dosage rates before efficacy is considered.

Study results show 30.3% of difficult to treat patients taking erenumab saw at least a 50% reduction in monthly migraine days.

Peter Goadsby, M.B., B.S., Director of the NIHR- Wellcome Trust King’s Clinical Research, London, Professor of Neurology, University of California at San Francisco, explained the benefits of the recent FDA approval of the gammaCore non-invasive vagal nerve stimulator on patients suffering from cluster headaches.

Andres Kanner, MD, Professor of Clinical Neurology, Chief of Epilepsy Division from the University of Miami Miller School of Medicine addressed that there were several medications in the pipeline being tested for different aspects of epilepsy treatment.

AT AAN 2017, Andres Kanner, MD, Professor of Clinical Neurology, Chief of Epilepsy Division from the University of Miami Miller School of Medicine spoke with MD Magazine about the latest advancements in epilepsy research.

Larry Altstiel, MD, PhD, EVP, Chief Medical Officer, vTv Therapeutics also discussed their team’s programs in type 2 diabetes. One is an activator of an enzyme called glucocynase – a master regulator for glucose in the body. According to Altstiel, when glucose is too high, it either shuns it off to energy production or stores it in the form of glycogen. It’s an insulin independent way of how the body controls glucose.

“This phase 2b study did exactly what we wanted a phase 2 study to do, which was to establish a patient population in mild patients and also find a safe and well tolerated dose,†said Larry Altstiel, MD, PhD.